LYTIR

Company · RLMD

Relmada Therapeutics, Inc.

Name as listed on its exchange; filed with the SEC as RELMADA THERAPEUTICS, INC.

Nasdaq's symbol directory lists RLMD on Nasdaq as “Relmada Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 4 occasions ($1.7M); 2 filings by holders of 5% or more.

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Maged Shenouda, Chief Financial Officer bought on 2 days latest Sep 10, 2026 bought $844K
  2. Sergio Traversa, Chief Executive Officer bought on 2 days latest Sep 10, 2026 bought $828K
Every trade (4)
  1. BUYSergio Traversa, Chief Executive Officer bought Sep 10, 2026 100,000 shares filing $410K
  2. BUYMaged Shenouda, Chief Financial Officer bought Sep 10, 2026 79,800 shares filing $339K
  3. BUYMaged Shenouda, Chief Financial Officer bought Sep 9, 2026 120,200 shares filing $505K
  4. BUYSergio Traversa, Chief Executive Officer bought Sep 9, 2026 100,000 shares filing $418K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Squadron Capital Management LLC filed Aug 14, 2026 Schedule 13G/A passive filing 7%
  2. MILLENNIUM MANAGEMENT LLC filed Jun 22, 2026 Schedule 13G passive filing 4.4%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.